arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

GeneDx Holdings Corp.

WGS
$77.19 ▲ +7.51 (+10.78%) at close
Healthcare ·Services-Health Services ·USServices-Health Services
26 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

GeneDx Holdings Corp. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3B
Dividend Yield
Revenue Growth 17.4%
Op. Margin -56.2%
ROIC -16.5%
FCF / Share $-1.32
Trailing P/E
Price / Book 9.0x
FCF Yield
Debt / Equity 0.39
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$102.25M
↑ +17.4%
Net Income Profit after all expenses
$-63.32M
↓ -869.8%
Operating Margin Operating profit as % of sales
-56.2%
↓ -377.7% 23th
FCF / Share Free cash flow per share
$-1.32
↓ -497.6%
Long-Term Debt Long-term obligations
$100.00M
↑ +83.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
27
Returns
37
Financial Health
58
Cash Quality
12

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 26 quarters